CLX Investment Company Announces Board Approval of New Corporate Name

MURRIETA, CA, Mar 31 (MARKET WIRE) --
CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda,
Incorporated, a developer and manufacturer of unique diagnostic tests for
the medical and non-medical markets, today announced that the Board of
Directors has met and approved CLX Medical, Inc. as the new name for the
company,
pending shareholder approval. The corporate name change requires majority
shareholder approval before it can take effect, and the Board expects to
initiate the process of gaining approval for the name change at the soonest
practicable date.

Earlier this month, the CLX Board met and determined that a name change
would be
beneficial in order to properly reflect CLX's current focus and its expected
future as a leader in the launch of medical diagnostic testing products. CLX is
currently preparing to initiate clinical trials for Zonda's HandiLab-C test
for Chlamydia as part of the process to achieve FDA clearance for the
product. With FDA clearance, CLX will seek to achieve widespread distribution
for the HandiLab-C within the U.S., as well as broader distribution into
worldwide markets.

In addition to Zonda's chlamydia product, CLX recently announced that the
company has identified a rapid diagnostic device for the medical market that it
has targeted for potential acquisition. As additional due diligence and
negotiations are undertaken, the company expects to pursue an initial
agreement in the form of a letter of intent for the acquisition of the
device. CLX has stated as its core focus to seek additional products and
technologies for the company to become involved with as they are presented.

"We believe that a new name will help to more closely identify CLX with
themedical industry, where its core focus lies," stated Vera Leonard, chief
executive officer of Zonda and CLX. "Management decided to keep the new
name close to the current name due to positive feedback the company had
received from its strategic partners and other in the industry. CLX had also
begun establishing industry relationships based on its work on the Zonda
chlamydia product, and it was determined that we could build upon our initial
work rather than starting our branding efforts over again with a new name."

"CLX Medical, Inc. is an ideal name for the company as we position it to
represent multiple medical diagnostic testing products and initiate distribution
into a variety of worldwide markets, including the U.S.," Ms. Leonard added.

To sign up to receive information by email directly from CLX Investment
Company when
new press releases, investor newsletters, SEC filings, or other information
is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 51% equity
interestin Zonda, Inc. CLX has also invested, and holds a common stock
position, in
ActionView International, Inc. (www.actionviewinternational.com), a
publicly traded global manufacturer and marketer of "smart" scrolling
advertising
billboards.

All statements included in this release, including statements regarding
potential
future plans and objectives of CLX Investments are forward-looking
statements. Such statements are necessarily subject to risks and
uncertainties, some of which are significant in scope and nature beyond CLX
Investments' control. There can be no assurance that such statements will
prove accurate. Actual results and future events could differ materially from
those anticipated in such statements depending on many factors. Historical
results are not necessarily indicative of future performance.

Contact:
Gemini Financial Communications
A. Beyer
951-677-8073
Email Contact

Copyright 2008, Market Wire, All rights reserved.

-0-